A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Key facts

Study ID

NCT06384807

Run by

Biohaven Therapeutics Ltd.

People needed

500

Starts

2024-04-22

Expected to finish

2028-02-01

Last updated by the study team

2026-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site-113 — Duarte, California, United States (enrolling)
• Site-112 — La Jolla, California, United States (enrolling)
• Site-111 — Palo Alto, California, United States (enrolling)
• Site-114 — Washington D.C., District of Columbia, United States (enrolling)
• Site-103 — Miami, Florida, United States (enrolling)
• Site-105 — Orlando, Florida, United States (enrolling)
• Site-115 — Tampa, Florida, United States (enrolling)
• Site-110 — Augusta, Georgia, United States (enrolling)
• Site-109 — Detroit, Michigan, United States (enrolling)
• Site-101 — St Louis, Missouri, United States (enrolling)
• Site-117 — New York, New York, United States (enrolling)
• Site-116 — Oklahoma City, Oklahoma, United States (enrolling)
• Site-108 — Philadelphia, Pennsylvania, United States (enrolling)
• Site-107 — Nashville, Tennessee, United States (enrolling)
• Site-104 — Dallas, Texas, United States (enrolling)
• Site-106 — West Valley City, Utah, United States (enrolling)
• Site-102 — Fairfax, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.